What stage does Healthspan Capital invest at?

Healthspan Capital invests at the Seed, Series A stages.

What is Healthspan Capital's typical check size?

Healthspan Capital typically writes checks of $5K.

What sectors does Healthspan Capital focus on?

Healthspan Capital focuses on Biotech, Longevity.

Where is Healthspan Capital located?

Healthspan Capital is headquartered in Oxford, GB.

Healthspan Capital

Venture capital

Oxford · Seed–Series A · 2 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Healthspan Capital

1,373 people in our graph share verified history with the Healthspan Capital team — schools, employers, funds. One of them is your warm intro.

Bastian Hasslingerunlockedknows Sebastian Brunemeier · together at PICUS CAPITAL (overlapped)

×2knows the team · via PICUS CAPITAL

×4knows the team · via McKinsey & Company

×2knows the team · via Vrije Universiteit Amsterdam (VU Amsterdam)

×2knows the team · via U.S. Department of State

knows the team · via Icahn School of Medicine at Mount Sinai

✨ Fox Verdict

Investment thesis

Healthspan Capital invests in a diversified portfolio of early-stage longevity biotechnology companies developing novel approaches to address aging, disease, and human lifespan. The fund leverages deep expertise in longevity biotech company creation and investment, backed by an extensive network of collaborators, advisors, and founders in the space. The rolling fund structure provides simple and flexible access for investors to participate in the longevity biotech sector.

Invests inBiotech Longevity Global Oxford

Source: firm website, verified Aug 6, 2026.

Stage

Seed–Series A

Check

$5K

Oxford, GB

Instruments

Equity

Founded

2021

Last 12 months

1 investment

Tracked investments

Team · 2 people

from curated & public directories

Sebastian Brunemeier· General Partner· Oxford, United Kingdomin 𝕏

Sebastian Brunemeier is a biotech investor and company builder focused on longevity and regenerative medicine. He is Co-Founder and General Partner of Healthspan Capital and has co-founded multiple longevity biotech companies including Cambrian Biopharma, where he served as Chief Investment Officer, and Samsara Therapeutics, where he served as Founder and COO. His background includes a DPhil in biochemistry of aging from the University of Oxford (which he left to co-found Cambrian), an MSc in molecular neuroscience and life science business management from the University of Amsterdam, and fellowships focused on aging research from the Fulbright Program, Scripps Research Institute, and Buck Institute for Research on Aging.

Colin Maraganore· Venture Fellow· Coloradoin

Colin Maraganore is a partner and co-founder at Bija Ventures, a venture capital firm focused on pre-seed and seed-stage therapeutics companies. He previously held operational roles at BioAge, Vium (acquired by Recursion), and Earli, and conducted research on neural addiction pathways at the University of Minnesota. Maraganore transitioned to venture capital to support technical founders in early-stage biotech with investors experienced in translational biology.

What they invest in

from 1 of 1 portfolio companies

AI & Machine Learning ×1Biotech ×1Deep Tech ×1Healthtech ×1Medical Devices ×1

HQs:United States×1

Investments · 1 tracked

founders shown can be your intro path

ImmuneBridgeimmunebridge.comMar 2026 · $7.7M

ImmuneBridge is a company working in cell-based cancer immunotherapy, including research on engineered natural killer cells for solid tumor treatment.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSan Francisco, US

Peretz Partensky(Executive Officer, Director)inStuart Alexander Jacobson(Executive Officer, Director)Nina Horowitz(Chief Executive Officer)inRui Tostoes(Chief Technology Officer)inAlicia Jackson(Director)

BoardDylan Morris(Director)

Co-investorsM Ventures NFX Gaingels Insight Partners One Way Ventures Sand Hill Angels

Portfolio news

latest coverage across their companies

ImmuneBridge Raises $7.7M Seed for Scalable Cell Therapies - TAMradar Funding Rounds Signals

ImmuneBridge · tamradar.com · Mar 24, 2026

Frequently asked questions

What stage does Healthspan Capital invest at?: Healthspan Capital invests at the Seed, Series A stages.
What is Healthspan Capital's typical check size?: Healthspan Capital typically writes checks of $5K.
What sectors does Healthspan Capital focus on?: Healthspan Capital focuses on Biotech, Longevity.
Where is Healthspan Capital located?: Healthspan Capital is headquartered in Oxford, GB.

Media · Podcasts & interviews

featuring the team

Sebastian Brunemeier, Partner at HealthSpan Capital talks to IBTV at Advanced Therapies Europe 2024

IBTV · Sebastian Brunemeier

Similar investors

Flagship Pioneering

Flagship Pioneering is a firm that creates and builds companies to pioneer breakthroughs in science and technology for people and the planet, active for over 25 years.

$500K – $10M

Future Positive Capital

Future Positive Capital is a European deep-tech fund that ties its entire thesis to the Future Cones foresight framework, explicitly focusing on preferable futures and positioning itself as a futures-thinking, systems-change VC rather than a generic climate or impact fund. The firm hard-wires impact into its economics by contractually indexing more than 100% of partners' carried interest to portfolio companies achieving both financial and measurable impact outcomes, while specializing in capital-intensive, highly technical step-change solutions for planetary-scale problems like robotics for wind farm operations, large-scale carbon removal, and ecosystem restoration.

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

5AM Ventures

5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.

$100K – $4M